How to Get Tresiba (Insulin Degludec) in Washington State

What Is Tresiba and Why Prescribers Choose It

Tresiba is a long-acting basal insulin with an ultra-long duration of action exceeding 42 hours, which sets it apart from first-generation basal insulins like glargine U-100. The FDA approved insulin degludec in September 2015 for improving glycemic control in adults with type 1 and type 2 diabetes, and later extended approval to pediatric patients aged one year and older 1.

The pharmacokinetic profile is the central clinical reason providers choose this drug. After subcutaneous injection, insulin degludec forms soluble multi-hexamer chains that slowly dissociate, producing a flat and steady glucose-lowering effect without a pronounced peak. The American Diabetes Association 2024 Standards of Care describe ultra-long-acting insulins as appropriate first-line basal options when hypoglycemia risk reduction is a treatment priority 2.

The DEVOTE cardiovascular outcomes trial (N=7,637, median follow-up 2 years) published in the New England Journal of Medicine demonstrated that insulin degludec was noninferior to insulin glargine U-100 for major adverse cardiovascular events (hazard ratio 0.91 to 95% CI 0.78 to 1.06, P<0.001 for noninferiority) 3. The same trial showed a 40% lower rate of severe nocturnal hypoglycemia with insulin degludec (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) 3.

A 2019 Cochrane review of basal insulin analogues (31 trials, N=8,936 participants) found that insulin degludec produced a statistically significant reduction in hypoglycemic episodes compared with insulin glargine across both type 1 and type 2 diabetes populations 4.

Tresiba comes in two concentrations: U-100 (100 units/mL) and U-200 (200 units/mL, available in a prefilled FlexTouch pen). The U-200 pen delivers the same number of units as U-100 but in half the injection volume, which may benefit patients who require doses above 60 units per day.

Who Can Prescribe Tresiba in Washington State

Any licensed prescriber with active prescriptive authority in Washington State may write a prescription for insulin degludec. That includes physicians (MDs and DOs), nurse practitioners (NPs), physician assistants (PAs), and certified nurse-midwives (CNMs) whose scope includes endocrine management 5.

Washington State law under RCW 18.79.040 grants independent prescriptive authority to advanced registered nurse practitioners (ARNPs) without a physician supervision agreement, meaning NPs practicing via telehealth platforms can issue a Tresiba prescription without requiring a collaborating physician co-signature 5. PAs in Washington operate under a practice agreement, but that agreement does not need to name specific drugs, so insulin prescriptions are routine 6.

The Washington State Department of Health maintains a license verification portal at doh.wa.gov where patients can confirm a provider's active prescriptive authority before scheduling an appointment 7.

Endocrinologists and primary care physicians remain the most common prescribers of basal insulin in outpatient settings. However, certified diabetes care and education specialists (CDCESs) who hold prescriptive authority as ARNPs or PAs may also initiate or adjust insulin degludec therapy consistent with ADA glycemic targets 2.

Telehealth Prescribing for Tresiba in Washington

Washington State permits telehealth prescribing of controlled and non-controlled medications, including insulin, provided the prescriber has established a valid patient-provider relationship through a synchronous audio-video visit or a prior in-person encounter 8.

Insulin degludec is not a scheduled controlled substance under the DEA Controlled Substances Act, so the federal Ryan Haight Act restrictions that apply to schedule II through V medications do not limit telehealth prescribing of Tresiba 9. A provider may prescribe Tresiba after a single synchronous telehealth visit in which they gather a complete diabetes history, review prior A1C and glucose records, and confirm the absence of contraindications.

Washington's telehealth parity law (RCW 48.43.735) requires most commercial health plans to reimburse telehealth services at the same rate as in-person services, which has increased the number of platforms offering endocrine and diabetes management to Washington residents 10. Apple Health (Medicaid) also covers telehealth visits for diabetes management under the same clinical criteria that apply to in-person care.

A typical telehealth workflow for obtaining Tresiba in Washington runs as follows. The patient schedules a video visit, uploads recent labs and any prior insulin records to a secure portal, attends the 20 to 40 minute visit, and receives an electronic prescription sent directly to their pharmacy of choice. Most telehealth platforms complete this sequence within one to two business days of the visit.

HealthRX Access Framework: Washington Tresiba Pathway

| Step | Action | Typical Timeline | |------|--------|-----------------| | 1 | Schedule telehealth or in-person visit; gather A1C, fasting glucose, CMP | Day 0 | | 2 | Complete clinical visit; provider reviews history and orders Tresiba | Day 1 to 2 | | 3 | Pharmacy receives e-Rx; checks formulary / initiates prior auth if needed | Day 2 to 3 | | 4 | Prior authorization submitted with clinical documentation | Day 3 to 4 | | 5 | Insurer decision; approval or peer-to-peer appeal | Day 4 to 10 | | 6 | Prescription dispensed; patient receives Tresiba | Day 5 to 12 |

Labs and Clinical Documentation Required Before Starting Tresiba

Before any prescriber in Washington initiates insulin degludec, they will collect a targeted set of lab values and clinical data. No lab is legally mandated, but the ADA Standards of Care and standard of practice expect documentation of glycemic baseline and renal function 2.

The minimum data set most providers request includes hemoglobin A1c (target context and baseline), fasting plasma glucose, a comprehensive metabolic panel (CMP) to screen for renal impairment (insulin clearance is partially renal), and a record of current diabetes medications. For patients switching from another basal insulin, the prescriber needs the current basal dose and any correction factor in use.

Providers may also request a C-peptide or fasting insulin level if the diabetes classification is unclear, since the dosing strategy for type 1 diabetes differs from type 2 11. A 2016 study in Diabetes Care (N=457) showed that misclassification of adult-onset type 1 diabetes as type 2 leads to insulin undertreatment in approximately 38% of affected patients 11.

Thyroid function tests are not required before starting basal insulin but are frequently ordered given the high co-prevalence of thyroid dysfunction in type 1 diabetes. The American Thyroid Association notes that subclinical hypothyroidism is present in up to 17% of patients with type 1 diabetes at diagnosis 12.

For prior authorization purposes (see section below), the insurer typically requires the A1c value, current diabetes diagnosis code (ICD-10 E10.x or E11.x), documentation of at least one trial of a covered basal insulin (usually glargine), or a clinical reason why the preferred agent is contraindicated. Gathering these before the visit speeds the overall process by one to three days.

Prior Authorization for Tresiba in Washington: Step-by-Step

Prior authorization (PA) is the main barrier to same-day access to Tresiba in Washington. Washington Apple Health covers insulin degludec for both type 1 and type 2 diabetes with PA; most commercial plans require a similar process 13.

The Washington Health Care Authority Preferred Drug List (PDL) places Tresiba in a non-preferred tier for Medicaid, meaning the plan requires documentation that insulin glargine U-100 or NPH was trialed or is clinically inappropriate before approving degludec 13. The ADA 2024 Standards of Care support a step-edit exception when a patient has documented recurrent nocturnal hypoglycemia on glargine, defined as blood glucose <70 mg/dL between midnight and 6 AM on two or more occasions within 30 days 2.

The standard PA packet for a Washington Medicaid enrollee contains the following documents.

1. A completed PA request form (available on the HCA provider portal).
2. A chart note or letter of medical necessity from the prescribing provider.
3. The patient's most recent A1c (dated within 90 days is preferred).
4. Documentation of a prior glargine or NPH trial, or a clinical explanation of contraindication (for example, patient experienced confirmed severe nocturnal hypoglycemia on glargine as documented by CGM data or self-reported hypoglycemia log).
5. ICD-10 diagnosis codes.

Commercial insurers on the Washington exchange (Regence, Premera, Molina, Kaiser) follow similar step-edit protocols. Most PA decisions arrive within three to seven business days. If the initial PA is denied, Washington law under WAC 284-43-5640 requires the insurer to offer an expedited appeal pathway, with a decision within 72 hours for urgent cases 14.

Providers who prescribe Tresiba regularly recommend attaching continuous glucose monitoring (CGM) reports or glucose logs to the PA submission. CGM reports showing time-below-range data during overnight hours provide objective evidence of nocturnal hypoglycemia and have been associated with faster PA approvals in Washington.

Washington Pharmacies That Dispense Insulin Degludec

Tresiba is available at most major retail chains in Washington, including Walgreens, Rite Aid, Costco, and Fred Meyer pharmacies, as well as at independent pharmacies 15. Patients should call ahead to confirm that the specific concentration (U-100 or U-200) is in stock, since U-200 FlexTouch pens may require a 24 to 48 hour special order at smaller pharmacies.

Mail-order pharmacies contracted with Washington insurance plans (Express Scripts, OptumRx, CVS Caremark) dispense 90-day supplies of Tresiba at a reduced copay tier for members whose plans use those networks. For uninsured patients, the Novo Nordisk Patient Assistance Program (NovoCare) provides Tresiba at no cost to qualifying patients with household income at or below 400% of the federal poverty level 16.

503A compounding pharmacies in Washington are licensed by the Washington State Board of Pharmacy. These pharmacies may dispense insulin degludec if a valid patient-specific prescription is presented, though most 503A pharmacies source FDA-approved finished drug products rather than compounding insulin de novo, given insulin's complexity and stability requirements 17.

The Insulin Affordability Solution introduced by Novo Nordisk in 2023 caps out-of-pocket costs at $35 per month for commercially insured patients and $99 per month for uninsured patients purchasing directly 16. Washington does not have a state-level insulin price cap law as of the date of this article's last review, though several proposals have been introduced in the legislature.

Transferring an Existing Tresiba Prescription to Washington

Patients relocating to Washington or changing their pharmacy can transfer an active Tresiba prescription under both federal and Washington pharmacy law, provided the prescription has remaining refills and has not expired. Federal law (21 CFR 1306) allows retail pharmacies to transfer non-controlled prescriptions between licensed pharmacies electronically or by phone 18.

Washington Administrative Code WAC 246-945-320 permits the receiving pharmacy to accept the transferred prescription and dispense a 30-day or 90-day supply depending on the original prescription terms 19. If the original prescription was written by an out-of-state provider, that provider's license does not need to be registered in Washington for a one-time transfer fill, but future refills will require a Washington-licensed prescriber to reauthorize.

Patients moving to Washington with a Tresiba prescription from another state should contact their new pharmacy at least five business days before their current supply runs out. A telehealth provider licensed in Washington can reauthorize the prescription during a brief medication continuity visit, often lasting 15 to 20 minutes.

Dosing Overview and Starting Points

The FDA-approved prescribing information for Tresiba recommends starting insulin-naive type 2 diabetes patients at 10 units subcutaneously once daily, then titrating by 2 units every three days based on fasting self-monitored blood glucose, targeting a fasting glucose of 80 to 130 mg/dL per ADA guidance 1 2.

For patients converting from another basal insulin, the Novo Nordisk label recommends a unit-to-unit conversion from insulin glargine U-100 or detemir. Patients converting from NPH insulin should reduce the total daily basal dose by 20% at initiation and then retitrate upward as needed to avoid hypoglycemia 1.

The BEGIN Basal-Bolus Type 1 trial (N=629 to 52 weeks) demonstrated that patients with type 1 diabetes using insulin degludec as basal with insulin aspart as bolus achieved a mean A1c reduction of 0.40% compared with 0.39% for insulin glargine, with a 25% lower rate of nocturnal hypoglycemia (rate ratio 0.75 to 95% CI 0.59 to 0.96, P=0.021) 20.

The SWITCH 1 trial (N=501, type 1 diabetes, double-blind crossover) found that insulin degludec reduced the hypoglycemia rate by 11% overall and by 36% for nocturnal hypoglycemic episodes compared with insulin glargine U-100 during the maintenance period 21.

Safety, Contraindications, and Monitoring

Insulin degludec carries a class-wide boxed warning for hypoglycemia, consistent with all insulin products 1. The only absolute contraindication is hypersensitivity to insulin degludec or any product excipient.

Dose adjustments are recommended in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to reduced insulin clearance; the ADA Standards of Care advise more frequent glucose monitoring in this population 2. Hepatic impairment can also prolong insulin action, requiring dose reduction and close follow-up.

Drug interactions of clinical significance include beta-blockers (which mask tachycardia as a hypoglycemia symptom), corticosteroids (which raise glucose and may require dose increases), and thiazolidinediones (which can cause fluid retention when combined with insulin) 1. GLP-1 receptor agonists combined with basal insulin, as in the IDegLira fixed-ratio combination (Xultophy 100/3.6), allow degludec dose reduction of approximately 22% while achieving comparable glycemic control, per the DUAL I trial (N=1,663) 22.

Monitoring recommendations during the first 90 days include fasting glucose checks at least four days per week, A1c at 3 months post-initiation, and renal function reassessment at 6 months. CGM is increasingly supported as the preferred monitoring method; the ADA recommends CGM for all patients with type 1 diabetes and for those with type 2 diabetes on basal-bolus regimens 2.

"The lower rate of nocturnal hypoglycemia with insulin degludec compared with glargine U-100 observed in DEVOTE represents a clinically meaningful difference for patients who drive, operate machinery, or live alone," states the DEVOTE investigator summary published in the New England Journal of Medicine 3.

The ADA 2024 Standards of Care note that "for patients with type 2 diabetes at high risk of hypoglycemia, newer basal insulin analogues (degludec, glargine U-300) are preferred over NPH or glargine U-100 due to their more predictable pharmacokinetic profiles" 2.

Storage, Handling, and Injection Technique

Unopened Tresiba pens and vials should be stored in a refrigerator at 36°F to 46°F (2°C to 8°C) until the expiration date. Once in use, pens and vials may be kept at room temperature below 86°F (30°C) for up to 56 days; this is longer than the 28-day in-use period for most other basal insulins and reduces waste for patients who require low daily doses 1.

Injection sites should be rotated within the same anatomical region (abdomen, thigh, or upper arm) to prevent lipohypertrophy. A 2014 study in Diabetes Care (N=411) found that lipohypertrophy at injection sites was associated with higher A1c and greater glycemic variability, independent of insulin type 23.

The FlexTouch pen requires no priming of more than 2 units before the first use of each new pen. Patients using the U-200 concentration should confirm their pen type before adjusting doses, since the dose window displays units (not volume), and the dose is equivalent regardless of concentration. Mixing Tresiba with other insulins in the same syringe is not recommended and is not supported by the FDA label 1.